IJSR International Journal of Scientific Research 2277 - 8179 Indian Society for Health and Advanced Research ijsr-7-8-16309 Original Research Paper Use of allogenic bone graft in treatment of Benign Osteolytic lesions Shikhar Dogra Dr. Dr Nidhi Kushwah Dr. August 2018 7 8 01 02 ABSTRACT

 In management of osteolytic lesions of bone definitive treatment involve intralesional excision and filling of the bone defect.1,2 Various material

such as autologous bone graft3, allogenic bone graft [4], [5], synthetic materials including calcium phosphate6, calcium hydroxy apatite7, have been
used with variable results. Allogenic Bone Graft (ABG) have got distinct advantage of being available in sufficient quantity without the risk of
donor site morbidity and doesn‘t warrant a second surgery for removal. From 2011 to 2013 , 8 consecutive benign osteolytic lesions (3 cases each of
of aneurysmal and simple bone cysts and 2 cases of Giant Cell Tumour) were treated by intralesional curettage and bone grafting using deep freezed
gamma irradiated allogenic bone graft either alone or in combination with autogenic bone graft/ bone marrow aspirate. All the patients were
randomly allocated to either vancomycin impregnated allogenic bone graft group (n=5) or simple allogenic bone graft group (n=3). The age range
of studied patients was from 14 to 43 years. Vancomycin impregnated allogenic bone graft appears to be a safe & effective filler, without any
systemic local and adverse effects, for bone defects secondary to benign osteolytic lesions. None of the patients develop postoperative infection.
All the eight osteolytic lesions in the study healed with the use of allogenic bone graft.